NCT04142047

Brief Summary

The investigators are studying whether metabolic abnormalities in calf (leg) muscle in older people with and others without HIV are associated with decreased abilities to exercise.

Trial Health

77
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
200

participants targeted

Target at P75+ for all trials

Timeline
14mo left

Started Jan 2019

Longer than P75 for all trials

Geographic Reach
1 country

1 active site

Status
recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Progress86%
Jan 2019Jul 2027

Study Start

First participant enrolled

January 3, 2019

Completed
10 months until next milestone

First Submitted

Initial submission to the registry

October 25, 2019

Completed
4 days until next milestone

First Posted

Study publicly available on registry

October 29, 2019

Completed
7.7 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

July 1, 2027

Expected
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

July 1, 2027

Last Updated

March 9, 2026

Status Verified

March 1, 2026

Enrollment Period

8.5 years

First QC Date

October 25, 2019

Last Update Submit

March 6, 2026

Conditions

Outcome Measures

Primary Outcomes (3)

  • Maximal mitochondrial oxidative capacity (VmaxPCr)

    Maximal oxidative capacity of leg muscle measured by 31P Magnetic Resonance Spectroscopy (MRS)

    Baseline

  • Rate of PCr decline during plantar flexion exercise

    Baseline

  • Six minute walk distance

    Baseline

Secondary Outcomes (3)

  • Skeletal muscle fat content

    Baseline

  • Gait speed

    Baseline

  • Frailty status (as measured by the Fried Frailty Index)

    Baseline

Study Arms (2)

HIV

Participants (ages 60 and above) with HIV

Control

Participants (ages 60 and above) without HIV

Eligibility Criteria

Age60 Years - 90 Years
Sexall
Healthy VolunteersYes
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

People with and without HIV, ages 60 and above will be enrolled

You may qualify if:

  • Participants who are \>= 60 years of age
  • HIV serostatus positive participants on stable antiretroviral therapy (ART) (no regimen change in last month) with undetectable HIV viral load (\<100 copies).
  • HIV serostatus negative participants

You may not qualify if:

  • Unable to understand the risks, benefits, and alternatives of participation and give meaningful consent
  • Contraindications to MRI
  • Significant cardiovascular, pulmonary or musculoskeletal or orthopedic disease that significantly limits exercise capacity
  • Significant lower extremity peripheral vascular disease.
  • Weight greater than 350 lbs
  • Cognitive or speech impairments that would limit completion of questionnaires or fatigue reporting.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Johns Hopkins Hospital

Baltimore, Maryland, 21287, United States

RECRUITING

Biospecimen

Retention: SAMPLES WITH DNA

Blood Specimens

MeSH Terms

Conditions

HIV Infections

Condition Hierarchy (Ancestors)

Blood-Borne InfectionsCommunicable DiseasesInfectionsSexually Transmitted Diseases, ViralSexually Transmitted DiseasesLentivirus InfectionsRetroviridae InfectionsRNA Virus InfectionsVirus DiseasesGenital DiseasesUrogenital DiseasesImmunologic Deficiency SyndromesImmune System Diseases

Study Officials

  • Robert G Weiss, MD

    Johns Hopkins University

    PRINCIPAL INVESTIGATOR

Central Study Contacts

Maria Esteban, RN, BSN

CONTACT

Tricia Steinberg, RN, MSN

CONTACT

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
PROSPECTIVE
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

October 25, 2019

First Posted

October 29, 2019

Study Start

January 3, 2019

Primary Completion (Estimated)

July 1, 2027

Study Completion (Estimated)

July 1, 2027

Last Updated

March 9, 2026

Record last verified: 2026-03

Locations